News

The distribution rights to fenofibrate were acquired earlier this year and, as previously announced, ANI had expected to transition these products to the ANI label in the second

WAVE’s DMD program is based on preclinical data demonstrating an approximate 25-fold improvement in exon-skipping efficiency compared to drisapersen and eteplirsen, suggesting the potential for improved potency and

Taiho Ventures will be investing globally in the start-up companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit

Under the deal, Incyte will make a $140m upfront payment to Ariad plus pay royalties of up to 50% on European sales of Iclusig. Incyte will also take

Janssen Biotech and AbbVie company Pharmacyclics are jointly developing and commercializing Imbruvica, which blocks a specific protein called Bruton’s tyrosine kinase. The Imbruvica labeling now includes OS results

Hotung Group, and CDIB Capital Management, led the round with continued participation from existing investors, Eminent II VC, Hua Nan Venture Capital, President International Development and UMC Capital

As its first official partnership for this program, Immunovaccine will collaborate with experts in this field at UConn Health on a preclinical study to evaluate the immunologic and

Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used for the treatment

The study (NCT02415127) has reached its target enrollment of 90 patients at four sites in the United States, and top-line results are expected by the end of 2016.